EMA Withdrawn: Daliresp (roflumilast) — AstraZeneca AB

View source ↗

Summary

The EMA document indicates that Daliresp (roflumilast) has been withdrawn from the market in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daliresp (roflumilast)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: AstraZeneca AB. Decision date: 03/11/2016